P17.24 * OUTCOME OF GLIOBLASTOMA IN YOUNG PATIENTS: A SINGLE INSTITUTION EXPERIENCE

Abstract

GBM is the most frequent brain tumor affecting adults. More than 80% of the patients are older than 50. Unfortunately the prognosis remains poor with a median overall survival of 14.6% and a 5 years survival of 9.8%. Between January 2002 and November 2013, 16 patients (7 men and 9 women; median age 40; range 26-50) affected by GBM were followed at our Institution. All patients had a diagnosis of GBM. Thirteen patients (81%) had a primary GBM, 3 patients (19%) had a secondary GBM arising from a low grade glioma diagnosed 3.6 years before (1-6 years). Eleven patients were radically operated (69%), 5 patients were submitted to partial exeresis (31%). After surgery, 13 patients (81%) received concomitant chemo- and radiotherapy (RT) (Stupp regimen); 3 patients were not submitted to RT (19%) as they received it years before, after the diagnosis of low grade glioma. Among the patients receiving chemoRT, 12 patients (92%) were submitted to adjuvant chemotherapy following Stupp regimen (number of cycles: 3-12), 1 patient (8%) died before starting adjuvant chemotherapy due to disease progression. Among the patients with a secondary GBM, 2 (67%) received Temozolomide as adjuvant treatment post-surgery, 1 patients (33%) received BCNU chemotherapy. Median time to progression (TTP) among the patients having completed adjuvant chemotherapy is 20 months (range 3-108). Among all the 16 patients described, 7 patients (44%) are alive at a median time of 32.7 months (range 6-90), 9 patients (56%) died and had a median overall survival (OS) of 27.4 months (range 4-108). Globally, patients under 50 affected by GBM have a longer median TTP and OS than patients over 50. Such a situation can be determined by the best Perfomance Status, the absence of comorbidities and the best physical reserve of the patients under 50 compared to the ones of older patients. Further studies are needed to evaluate the outcome of GBM in patients under 50.